Organization named in the records

Relypsa

Named in 3 passages across 2 documents.

Mentions of Relypsa in the public Epstein records, with citations.

Ask the documents about Relypsa Search every mention

--}}

Being named in these documents is not an accusation or evidence of wrongdoing. This page reflects only what the public records literally contain, with citations to the original sources.

Where Relypsa appears

3 total

ER 257 - CONFIDENTIAL James Niedel, MD, Ph.D., (70), Venture Partner, joined Sprout in May 2002 and helped found New Leaf in 2005. Jim will change his status to Venture Partner in NLV-III with the closing of the new fund. In this role, Jim...

Times Square Tower TEXT-001-HOUSE_OVERSIGHT_024003.txt p.1 View source release ↗

…with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Rob...

Times Square Tower TEXT-001-HOUSE_OVERSIGHT_024003.txt p.1 View source release ↗

…hese have included Pearl Therapeutics (NLV-I, exited in sale to Astra Zeneca, 2.5x multiple plus milestones), Relypsa (NLV-I,_ private initially, now public on NASDAQ: RLYP), Convergence/Calchan Pharmaceuticals (NLV-IL, one start up that su...

Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction IMAGES-007-HOUSE_OVERSIGHT_024045.txt p.1 View source release ↗

Also named alongside

New York New Leaf NEW LEAF VENTURES III, L.P Harvard Medical School U.S. Securities and Exchange Commission NEW LEAF VENTURE PARTNERS, L.L.C Boston Consulting Group New Leaf Ventures I, L.P All Sprout Funds U.S. Congress Amgen Auxilium

Want context across all of these passages at once?

Ask the documents about Relypsa